Eli Lilly’s trial evaluating Mounjaro in reducing cardiovascular risk met its endpoint, though missed analyst expectations.

Anavex's blarcasemine met its primary endpoints, improving cognition and function over a four year period in early-stage Alzheimer’s patients.

Lantern Pharma has completed targeted enrolment for its multi-centre Phase II HARMONIC trial of a disulfide small molecule, LP-300.

Idiopathic pulmonary fibrosis (IPF) is a progressive and often fatal lung disease characterised by the accumulation of scar tissue in the lungs, leading to respiratory failure.

AbbVie has reported topline outcomes from the first of two trials of the Phase III UP-AA programme, assessing Rinvoq (upadacitinib).

Eli Lilly’s Kisunla and Biogen/Eisai’s Leqembi can both continue to slow Alzheimer's cognitive decline after over three years of treatment.

Cognition Therapeutics’ therapy showed up to a 129% slowing of cognitive decline in mild Alzheimer’s disease patients.

Roche’s Alzheimer’s disease therapy has continued to show benefit for patients after 28 weeks in a long-term extension study.

Recognify Life Sciences has reported that its Phase IIb trial of inidascamine to treat CIAS failed to achieve its primary goal.

Filament Health has collaborated with UCL to provide its botanical psilocybin drug candidate, PEX010, for two Phase II research studies.

Windward Bio has launched the Phase II POLARIS trial of the recombinant, fully human monoclonal antibody, WIN378, in individuals with asthma.

Abivax's obefazimod resulted in an average 16.4% placebo-adjusted clinical remission rate in UC patients across the two trials.